Skip to main content
SpringerLink
Log in

Preservation of myocardium in transient ischemia by the thromboxane synthetase inhibitor UK 38.485

  • Original Papers
  • Published:
Research in Experimental Medicine

Summary

This study was performed to examine potential protective effects of UK 38.485, an inhibitor of thromboxane synthetase, in canine myocardium stressed by transient ischemia.

On anesthetized open-chest mongrel-dogs (n = 9) repeated ischemia (3 min) was produced by proximal, intermittent occlusion of the left anterior descending artery. A total of 18 occlusions after 3 mg UK 38.485/kg body wt. and 12 occlusions after 5 mg UK 38.485/kg body wt. were compared to a total of 24 occlusions under control conditions. In each experiment, 2–3 control occlusions and 3–4 therapy occlusions were performed.

The drug was applied i.v. in a dose of 3 or 5 mg/body wt. 30 min before the first therapy occlusion. In both groups, hemodynamics and energetics did not significantly change as compared to control.

The efficiency of the drug in protecting ischemically stressed myocardium was examined by (a) quantification of oxygen debt and oxygen repayment in the occlusion and reperfusion periods and (b) the amounts of inorganic phosphate, lactate, and potassium released in the first minute of reperfusion. Compared to control occlusions, premedication with either 3 or 5 mg UK 38.485 led to a significantly reduced oxygen debt combined with a significant decrease of the release of inorganic phosphate, lactate, and potassium. The protective effect is suggested to be mainly due to enhanced flow to ischemic areas.

Data obtained in this study suggest protective effects of the compound in the preservation of myocardium in transient ischemia and attest to the concept that thromboxane A2 may aggravate the metabolic and energetic situation of myocardium in circumstances with reduced oxygen supply.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Baller D, Bretschneider HJ, Hellige G (1979) Validity of myocardial oxygen consumption parameters. Clin Cardiol 2:317–327

    PubMed  Google Scholar 

  2. Bergman G, Daly R, Atkinson L, Rothman M, Richardson PJ, Jackson G (1981) Prostacyclin: Haemodynamic and metabolic effects in patients with coronary artery disease. Lancet 1:569–572

    PubMed  Google Scholar 

  3. Burke S, Lefer AM, Smith GM, Smith B (1983) Prevention of extension of ischemic damage following acute myocardial ischemia by dazoxiben, a new thromboxane synthetase inhibitor. Br J Clin Pharmacol 15:97S-101S

    PubMed  Google Scholar 

  4. Chiercha S, deCaterina R, Brunelli C, Crea F, Patrono C, Maseri A (1980) Low dose aspirin prevents thromboxane synthesis by platelets but not attacks of Prinzmetal angina. Circulation 62 [Suppl 3]:215

    Google Scholar 

  5. Coker S, Parratt JR, Ledingham IA, Zeitlin I (1981) Thromboxane and prostacyclin release from ischemic myocardium in relation to arrhythmias. Nature 291:323–324

    PubMed  Google Scholar 

  6. Coker S, Parratt JR (1983) Effects of dazoxiben on arrhythmias and ventricular fibrillation induced by coronary artery occlusion and reperfusion in anaesthetised greyhounds. Br J Clin Pharmacol 15:87S-95S

    PubMed  Google Scholar 

  7. Dazoxiben—Clinical prospects for a thromboxane synthetase inhibitor (1983) Edinburgh, March 26–27, 1982. Br J Clin Pharmacol [Suppl 1] 15

  8. Defreyn G, Deckmyn H, Vermylen J (1982) A thromboxane synthetase inhibitor reorients endoperoxide metabolism in whole blood towards prostacyclin and prostaglandin E2. Thromb Res 26:389–400

    PubMed  Google Scholar 

  9. Fischer S, Struppler M, Böhlig B, Bernutz C, Wober W, Weber PC (1983) The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK 38.,485, on prostanoid formation in man. Circulation 68:821–826

    PubMed  Google Scholar 

  10. Frishman WH, Christodolou J, Weksler B, Smithen C, Killip T, Scheidt S (1976) Aspirin in angina pectoris: effects on platelet aggregation, exercise tolerance and electrocardiographic manifestations of ischemia. Am Heart J 92:3–9

    PubMed  Google Scholar 

  11. Hall RJC, Dewar HA (1981) Safety of coronary arterial prostacyclin infusion. Lancet 1:949–951

    Google Scholar 

  12. Harris DM, Greenberg R, Phillips MB, Osman GH, Antonaccio MJ (1980) Effect of SQ80, 338 (1-(3-phenyl-2-propenyl)-1H-imidazole) on thromboxane synthetase activity and arachidonic acid-induced platelet aggregation and bronchoconstriction. In: Samuelsson B, Ramwell PW, Paoletti R (eds) Advances in Prostaglandin and Thromboxane Research, vol 6. Raven Press, New York, pp 437–441

    Google Scholar 

  13. Hirsh PD, Hillis LD, Campbell WD, Firth BG, Willerson JT (1981) Release of prosta glandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304:685–691

    PubMed  Google Scholar 

  14. Hoeft A, Korb H, Baller D, Wolpers HG, Hellige G, Bretschneider HJ (1983) Quantification of ischemic stress during repeated coronary artery occlusion in the dog. A method for validation of therapeutic effects. I. Estimation of O2 dept and O2 repayment. Basic Res Cardiol 79:27–37

    Google Scholar 

  15. Jentzer JH, Sonnenblick EH, Kirk ES (1979) Coronary and systemic vasomotor effects of prostacyclin: Implication for ischemic myocardium. In: Vane JR, Bergström S (eds) Prostacyclin. Raven Press, New York, pp 323–336

    Google Scholar 

  16. Korb H, Hoeft A, Baller D, Wolpers HG, Hellige G, Bretschneider HJ (1983) Quantification of ischemic stress during repeated coronary artery occlusion in the dog. A method for validation of therapeutic effects. II. Reproducibility of the release and uptake of electrolyte and substrates. Basic Res Cardiol 79:38–48

    Google Scholar 

  17. Kuzuya T, Tada M, Ohmori M, Inui M, Inoue M, Abe H, Yamagishi M, Kodoma K (1980) Altered metabolism of thromboxane A2 and prostaglandin I2 in patients with angina pectoris. Circulation 64 [Suppl 3]:275

    Google Scholar 

  18. Lewy RI, Smith JB, Silver MJ, Saia J, Walinsky P, Wiener L (1979) Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandins Med 2:243–248

    PubMed  Google Scholar 

  19. Moncada JR, Bunting S, Mullane K, Thorogood P, Vane J (1977) Imidazole: A selective inhibitor of thromboxane synthetase. Prostaglandins 13:611–618

    PubMed  Google Scholar 

  20. Moncada S, Vane JR (1979) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293–331

    Google Scholar 

  21. Needleman P, Wyche A, Raz A (1979) Platelet and blood vessel arachidonate metabolism and interactions. J Clin Invest 63:345–349

    PubMed  Google Scholar 

  22. Neri-Serneri GG, Gensini GF, Abbate R, Mugnaini C, Favilla S, Brunelli C, Chierchia S, Parodi O (1981) Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: Relationship to coronary pathoanatomy, risk factors, and clinical manifestations. Am Heart J 101:187–193

    Google Scholar 

  23. Parry MJ, Randall MJ, Hawkeswood E, Cross PE, Dickinson RP (1983) Inhibition of thromboxane synthesis and enhanced production of prostacyclin in blood after treatment with selective thromboxane synthetase inhibitor UK 38.485. Br J Pharmacol 77:547–551

    Google Scholar 

  24. Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ (1981) Inhibition of prostacyclin and platelet thromboxane A2 after low dose aspirin. N Engl J Med 304:76–79

    PubMed  Google Scholar 

  25. Robertson RM, Robertson D, Roberts J (1981) Thromboxane A2 in vasotonic angina pectoris. Evidence from direct measurements and inhibitor trials. N Engl J Med 304:998–1003

    PubMed  Google Scholar 

  26. Schrör K, Moncada S, Ubatuba FB, Vane JR (1978) Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. Eur J Pharmacol 47:103–114

    PubMed  Google Scholar 

  27. Schrör K, Smith EF, Bickerton M, Smith JB, Nicolaou KC, Magolda R, Lefer AM (1980) Preservation of the ischemic myocardium by pinane thromboxane. Am J Physiol 238:H87-H92

    PubMed  Google Scholar 

  28. Smith EF, Lefer AM, Smith JB (1980) Influence of thromboxane inhibition on the severity of myocardial ischemia in cats. Can J Physiol Pharmacol 58:294–300

    PubMed  Google Scholar 

  29. Szczecklik A, Gryglewski RJ (1981) Treatment of vascular disorders with prostacyclin. In: Lewis PJ, O'Grady J (eds) Clinical pharmacology of prostacyclin. Raven Press, New York, pp 159–167

    Google Scholar 

  30. Vermylen J, Deckmyn H (1983) Reorientation of prostaglandin endoperoxide metabolism by thromboxane synthetase inhibitor: In vitro and clinical observations. Br J Clin Pharmacol 15:17–22

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Abt. für Experimentelle Kardiologie, Zentrum Physiologie und Pathophysiologie, Universität Göttingen, Humboldtallee 23, D-3400, Göttingen, Federal Republic of Germany

    A. Hoeft, H. Korb, J. Böck, H. G. Wolpers & G. Hellige

  2. Laboratoires d'Études et de Recherches Synthelabo, D-8000, München 81, Federal Republic of Germany

    W. Wober

Authors
  1. A. Hoeft
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H. Korb
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Böck
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. G. Wolpers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. W. Wober
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Hellige
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Supported by the Deutsche Forschungsgemeinschaft SFB 89 — Kardiologie Göttingen

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hoeft, A., Korb, H., Böck, J. et al. Preservation of myocardium in transient ischemia by the thromboxane synthetase inhibitor UK 38.485. Res. Exp. Med. 186, 35–46 (1986). https://doi.org/10.1007/BF01851832

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01851832

Key words

Search

Navigation